# Diabetes Research Hub — Monitor Report
**Run date:** 2026-10-02 (automated review; no existing files modified)

**Headline:** No new data since the 2026-10-01 report. All five key outputs were last generated 2026-10-01 12:28–12:30, and `clinical_trials_latest.json` / `pubmed_recent_latest.json` are byte-identical to their 10-01 snapshots (verified with `cmp`). Findings in `monitor_report_2026-10-01.md` still stand; nothing new to escalate.

## File System Status
| File | Last modified | Status |
|---|---|---|
| hub_monitor_report.md | 2026-10-01 | Fresh (1 day) |
| clinical_trials_latest.json | 2026-10-01 | Fresh; = snapshot_2026-10-01 |
| pubmed_recent_latest.json | 2026-10-01 | Fresh; = snapshot_2026-10-01 |
| literature_gap_data.json / _report.md | 2026-10-01 | Fresh |
| Diabetes_Research_Tracker.xlsx | 2026-07-17 | **STALE, 77 days** |
| .~lock.Diabetes_Research_Tracker.xlsx# | 2026-03-15 | Stale lock file (~200 d) |

Git: `main` ahead of origin by 1 commit (ce2bf84, 10-01); many modified caches uncommitted. Confirm push is intended.

## Clinical Trial Changes
Nothing new vs 10-01 (906 trials). Carry-over items: NCT06109311 (Lilly orforglipron Ph3, results posted 10-01); NCT07817251 (Novo CagriSema, NOT_YET_RECRUITING → RECRUITING); NCT05757713 (Sanofi teplizumab pediatric) still unconfirmed in the registry pull. 143 Phase 3 trials, 282 recruiting. Registry-posted results = unreviewed (BRONZE) until tied to a verified paper.

## PubMed Highlights
Unchanged (168 papers, 17 domains). Top item remains PMID 42815506 (Lancet, orforglipron CV safety vs glargine), plus cross-domain review papers 42808923, 42803913, 42812898, 42763732. Zimislecel: 0 hits (continues).

## Gap Analysis Summary
22 of 435 pairs are tied at score 100.0, so the score no longer discriminates. Top five (tie order only): Beta Cell Regen × Health Equity (0 joint pubs), Insulin Resistance × Islet Transplant (1), Islet Transplant × GWAS (0), Islet Transplant × Personalized Nutr (0), Islet Transplant × Drug Repurposing (0). Many ties involve small-volume domains (Islet Transplant 254 pubs), so a terminology mismatch is plausible. gap_tiers.json lists Gap #2 (Health Equity) as GOLD.

## Breaking News (web, last ~7 days)
Searches surfaced no new Phase 3 readout or FDA action beyond what the hub already holds. Confirmed already tracked: Kerendia T1D-CKD (action 2026-09-16, in fda_approval_verification.json), Onswik/efsitora (2026-09-23), Beta Bionics Mint patch pump (cleared ~09-15). Teplizumab Stage 3 pediatric accelerated approval (2026-06-12) is older than the 7-day window. [Confidence: Likely; search snippets are thin.]

## Recommended Actions
1. Update Diabetes_Research_Tracker.xlsx (77 days stale) with NCT06109311, NCT07817251, Onswik, Kerendia T1D-CKD.
2. Read PMID 42815506 abstract, verify HR/PMID, then consider adding to Research_Findings_Summary.md.
3. Manually check NCT05757713 on ClinicalTrials.gov.
4. Replace the saturated gap score with a tie-breaking metric (e.g., observed/expected ratio with confidence intervals).
5. Run `git log origin/main..` and push if intended; delete the stale .~lock file.
6. Scripts are current (1 day); no refresh required.
